Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
- Update frequency
- every day
- Average duration
- 26 minutes
- Episodes
- 1069
- Years Active
- 2020 - 2025
S2-E40.2 - Discussing Comprehensive Care Models For NAFLD - Providers Respond
Stephen Harrison and Louise Campbell discuss their reactions to the recent paper, "Defining Comprehensive Models of Care for NAFLD." Stephen takes the perspective of a practicing hepato…
S2-E40.1 - Discussing Comprehensive Care Models for NAFLD - Jeff Lazarus Presents Research
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join the Surfers to discuss how they developed the care models for their recent paper, "Defining Comprehensive Models of Care…
S2-E40 - Discussing Comprehensive Care Models for NAFLD
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join the Surfers to discuss their recent paper, "Defining Comprehensive Models of Care for NAFLD." In this vitally important …
S2-E39.3 - 20K Celebration Interview With Jörn Schattenberg and Ian Rowe
This week's celebration podcast featured interviews including seven of our favorite Surfers. In this week's conversations, we are publishing the interviews in full. Third up, Jörn Schat…
S2-E39.2 - 20K Celebration Interviews With Stephen Harrison and Naim Alkhouri
This week's celebration podcast featured interviews including seven of our favorite Surfers. In this week's conversations, we are publishing the interviews in full. Second up: Stephen H…
S2-E39.1 - 20K celebration Interview with Donna Cryer
This week's celebration podcast featured interviews including seven of our favorite Surfers. In this week's conversations, we are publishing the interviews in full. First up: Donna Crye…
S2-E39 - Celebrating Two Milestones for SurfingNASH!
Seven of our favorite Surfers join together to celebrate 20,000 Buzzsprout downloads and our one-year anniversary of moving to Buzzsprout.
Louise Campbell and Roger Green interview Steph…
S2-E38.3 - Creating an Ecosystem of Community Physicians To Support Clinical Trials
Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Di…
S2-E38.2 - Building a Culture That Encourages Patient Participation
Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Di…
S2-E38.1 - Motivating Underserved Patients to Participate in Clinical Trials
Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Di…
S2-E38 - Increasing Diversity in the Clinical Trial Patient Population
Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Di…
S2-E37.3 - Spreading the NASH Message Throughout the Broader Community Of Healthcare Practitioners
Jörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets. This conversation focuses on the challeng…
S2-E37.2 - NASH Diagnostics Provide a Natural Brake on Overly Broad Adoption of NASH Drugs
Jörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets. This conversation focuses on the unique c…
S2-E37.1 - Key Reasons the NASH Drug Market Will Evolve Differently From Statins
Jörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets. In this conversation, each panelist ident…
S2-E37 - Why the NASH Market Is Different From Statins
Jörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets.
It has been common for industry advocates …
S2-E36.3 - From the #ILC2021 Wrap-up: Focus on Care Pathways and Treatment Roles
Quentin Anstee, Louise Campbell, Stephen Harrison, Mazen Noureddin, Ian Rowe and Roger Green convene to review #ILC2021 and share key takeaways and insights. This conversation covers is…
S2-E36.2 - From The #ILC2021 Wrap-Up: Focus On Drug Development
Quentin Anstee, Louise Campbell, Stephen Harrison, Mazen Noureddin, Ian Rowe and Roger Green convene to review #ILC2021 and share key takeaways and insights. This conversation covers is…
S2-E36.1 - From the #ILC2021 Wrap-up: Focus on Diagnostics
Quentin Anstee, Louise Campbell, Stephen Harrison, Mazen Noureddin, Ian Rowe and Roger Green convene to review #ILC2021 and share key takeaways and insights. This conversation covers is…
S2-E36 - #ILC2021 Wrap-Up: Big Issues, Key Takeaways, Remaining Issues
Key opinion leaders Quentin Anstee, Mazen Noureddin and Ian Rowe join Stephen, Louise and Roger to discuss the major lessons and dangling questions from #ILC2021.
The group shares perspe…
S2-E35 - #ILC2021 Day Four - Promising Times Ahead, Maybe With a Few More Bumps In the Road
Donna Cryer, Vlad Ratziu, Michael Charlton and Mazen Noureddin join Roger Green in reviewing the final day of #ILC 2021.
The conversation revolved around three themes: non-invasive tests…